Retinoid receptors in gastric cancer: Expression and influence on prognosis

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 1809-1817

  Hu, Kong Wang ^a   Chen, Fei Hu ^a   Ge, Jin Fang ^a   Cao, Li Yu ^a   Li, Hao ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

ATRA; Prognostic factors; Retinoic acid receptors; Stomach neoplasms; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; MESSENGER RNA; RETINOIC ACID; RETINOIC ACID RECEPTOR;

ADENOCARCINOMA; AGED; ARTICLE; CANCER STAGING; ENZYME IMMUNOASSAY; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH TUMOR; SURVIVAL RATE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, RETINOIC ACID; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS; SURVIVAL RATE; TRETINOIN;

EID: 84872678307     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.1809     Document Type: Article

References (74)

1. Abu J, Batuwangala M, Herbert K, Symonds P (2005). Retinoic acid and retinoid receptors: potential chemopreventive and therapeutic role in cervical cancer. Lancet Oncol, 6, 712-20.
2. Aebi S, Kröning R, Cenni B, et al (1997). All-trans retinoic acid enhances cisplatin-induced apoptosis in human ovarian adenocarcinoma and in squamous head and neck cancer cells. Clin Cancer Res, 3, 2033-8.
3. Altucci L, Gronemeyer H (2001). The promise of retinoids to fight against cancer. Nat Rev Cancer, 1, 181-93.
4. Ben Ayed-Guerfali D, Benhaj K, Khabir A, et al (2011). Hypermethylation of tumor-related genes in Tunisian patients with gastric carcinoma: clinical and biological significance. J Surg Oncol, 103, 687-94.
5. Chakravarti N, Mathur M, Bahadur S Kumar Shukla N, Ralhan R (2003). Retinoic acid receptor alpha as a prognostic indicator in oral squamous cell carcinoma. Int J Cancer, 103, 544-9.
6. Chao TY, Jiang SY, Shyu RY, Yeh MY, Chu TM (1997). Alltrans retinoic acid decreases susceptibility of a gastric cancer cell line to lymphokine-activated killer cytotoxicity. Br J Cancer, 75, 1284-90.
7. Coelho SM, Vaisman M, Carvalho DP (2005). Tumour redifferentiation effect of retinoic acid: a novel therapeutic approach for advanced thyroid cancer. Curr Pharm Des, 11, 2525-31.
8. Cox DR (1972). Regression models and life tables (with discussion). J R Stat Soc B, 34, 187-220.
9. Crew KD, Neugut AI (2006). Epidemiology of gastric cancer. World J Gastroenterol, 12, 354-62.
10. Crowe DL, Kim R, Chandraratna RA (2003). Retinoic acid differentially regulates cancer cell proliferation via dosedependent modulation of the mitogen-activated protein kinase pathway. Mol Cancer Res, 1, 532-40.
11. Cunningham SC, Kamangar F, Kim MP, et al (2005). Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. J Gastrointest Surg, 9, 718-25.
12. Deng J, Liang H, Sun D, Wang D, Pan Y (2010). Suitability of 7th UICC N stage for predicting the overall survival of gastric cancer patients after curative resection in China. Ann Surg Oncol, 17, 1259-66.
13. Edge SB, Byrd DR, Compton CC, et al (2010). editors. AJCC cancer staging manual. 7th edition ed. NewYork, NY: Springer.
14. Evans R (1998). The steroid and thyroid hormone receptor superfamily. Science, 13, 889-95.
15. Farol LT, Hymes KB (2004). Bexarotene: a clinical review. Expert Rev Anticancer Ther, 4, 180-8.
16. Garattini E, Gianni M, Terao M (2007). Cytodifferentiation by retinoids, a novel therapeutic option in oncology: rational combinations with other therapeutic agents. Vitam Horm, 75, 301-54.
17. Gobbi PG, Villano L, Pozzoli D, et al (2011). Improving the AJCC/TNM classification for use in early gastric cancer. J Gastrointest Surg, 15, 935-41.
18. Gunderson LL, Sosin H (1982). Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys, 8, 1-11.
19. Gyftopoulos K, Perimenis P, Sotiropoulou-Bonikou G et al (2000). Immunohistochemical detection of retinoic acid receptor-alpha in prostate carcinoma: correlation with proliferative activity and tumor grade. Int Urol Nephrol, 32, 263-9.
20. Hamilton SR, Aaltonen LA (2000). Pathology and genetics. Tumors of the digestive system. Geneva: WHO Press pp 1-314.
21. Hayashi K, Yokozaki H, Goodison S, et al (2001). Inactivation of retinoic acid receptor beta by promoter CpG hypermethylation in gastric cancer. Differentiation, 68, 13-21.
22. Horn TL, Torres KE, Naylor JM, et al (2007). Subchronic toxicity and toxicogenomic evaluation of tamoxifen citrate + bexarotene in female rats. Toxicol Sci, 99, 612-27.
23. Hsu SM, Reiner L, Fanger H (1981). Use of avidin-biotinperoxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem, 29, 577-80.
24. Huang SL, Shyu RY, Yeh MY, Jiang SY (2002). The retinoidinducible gene I: effect on apoptosis and mitogen-activated kinase signal pathways. Anticancer Res, 22, 799-804.
25. Jiang CG, Wang ZN, Sun Z, et al (2011). Clinicopathologic characteristics and prognosis of signet ring cell carcinoma of the stomach: results from a Chinese mono-institutional study. J Surg Oncol, 103, 700-3.
26. Jiang SY, Shen SR, Shyu RY, et al (1999). Expression of nuclear retinoid receptors in normal, premalignant and malignant gastric tissues determined by in situ hybridization. Br J Cancer, 80, 206-14.
27. Jozan S, Lafon C (1996). Enhancement of cisplatin cytotoxicity by all-trans retinoic acid in a human ovarian carcinoma cell line (OVCCR1) is characterized by apoptosis. Proc Am Assoc Cancer Res, 37, 414.
28. Jozan S, Paute S, Courtade-Saidi M et al (2002). All trans retinoic acid enhances CDDP-induced apoptosis: modulation of the CDDP effect on cell cycle progression. Int J Oncol, 20, 1289-95.
29. Kaplan EL, Meier P (1958). Nonparametric estimations from incomplete observations. J Am Stat Assoc, 53, 457-81.
30. Karam SM, Hassan WM, John R (2005). Expression of retinoid receptors in multiple cell lineages in the gastric mucosae of mice and humans. J Gastroenterol Hepatol, 20, 1892-9.
31. Khedmat H, Panahian M, Mashahdian M, Rajabpour MV, Zendehdel K (2011). Prognostic factors and survival in stomach cancer - analysis of 15 years of data from a referral hospital in iran and evaluation of international variation. Onkologie, 34, 178-82.
32. Khuri FR, Lippman SM, Spitz MR, Lotan R, Hong WK (1997). Molecular epidemiology and retinoid chemoprevention of head and neck cancer. J Natl Cancer Inst, 89, 199-211.
33. Kim JH, Choi YK, Kwon HJ et al (2004). Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1. J Gastroenterol Hepatol, 19, 218-24.
34. Koike H, Ichikawa D, Ikoma H, et al (2005). Comparison of serum aberrant methylation and conventional tumor markers in gastric cancer patients. Hepatogastroenterology, 52, 1293-6.
35. Kunisaki C, Ishino J, Nakajima S, et al (2006). Outcomes of mass screening for gastric carcinoma. Ann Surg Oncol, 13, 221-8.
36. Lin XF, Zhao BX, Chen HZ, et al (2004). RXRalpha acts as a carrier for TR3 nuclear export in a 9-cis retinoic aciddependent manner in gastric cancer cells. J Cell Sci, 117, 5609-21.
37. Lippman SM, Benner SE, Hong WK (1994). Cancer chemoprevention. J Clin Oncol, 12, 851-73.
38. Lippman SM, Lee JJ, Karp DD et al (2001). Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst, 93, 605-18.
39. Liu G, Wu M, Levi G, Ferrari N (1998). Inhibition of cancer cell growth by all-trans retinoic acid and its analog N-(4- hydroxyphenyl) retinamide: a possible mechanism of action via regulation of retinoid receptors expression. Int J Cancer, 78, 248-54.
40. Liu S, Wu Q, Chen ZM, Su WJ (2001). The effect pathway of retinoic acid through regulation of retinoic acid receptor alpha in gastric cancer cells. World J Gastroenterol, 7, 662-6.
41. Mangelsdorf DJ, Umesono K, Evans RM (1994). The retinoid receptors. In: Sporn MB, Roberts AB, Goodman DS, eds. The Retinoids: Biology, Chemistry, and Medicine, 2nd Edition. New York: Raven Press pp 319-50.
42. Mantel N (1966). Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep, 50, 163-70.
43. Mehta K (2003). Retinoids as regulators of gene transcription. J Biol Regul Homeost Agents, 17, 1-12.
44. Msika S, Benhamiche AM, Jouve JL, Rat P, Faivre J (2000). Prognostic factors after curative resection for gastric cancer. A population-based study. Eur J Cancer, 36, 390-6.
45. Nehme A, Varadarajan P, Sellakumar G et al (2001). Modulation of docetaxel-induced apoptosis and cell cycle arrest by all-trans retinoic acid in prostate cancer cells. Br J Cancer, 84, 1571-6.
46. Parkin DM (2001). Global cancer statistics in the year 2000. Lancet Oncol, 29, 533-43.
47. Pasquali D, Rossi V, Bellastella G, Bellastella A, Sinisi AA (2006). Natural and synthetic retinoids in prostate cancer. Curr Pharm Des, 12, 1923-9.
48. Peto R, Pike MC, Armitage P, et al (1977). Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer, 35, 1-39.
49. Petrie K, Zelent A, Waxman S (2009). Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol, 16, 84-91.
50. Pocock SJ, Simon R (1975). Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics, 31, 103-15.
51. Reynolds CP (2000). Differentiating agents in pediatric malignancies: retinoids in neuroblastoma. Curr Oncol Rep, 2, 511-8.
52. Richter F, Joyce A, Fromowitz F, et al (2002). Immunohistochemical localization of the retinoic Acid receptors in human prostate. J Androl, 23, 830-8.
53. Riecken EO, Rosewicz S (1999). Retinoids in pancreatic cancer. Ann Oncol, 4, 197-200.
54. Sachs L (1978a). Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia. Nature, 274, 535-9.
55. Sachs L (1978b). The differentiation of myeloid leukaemia cells:new possibilities for therapy. Br J Haematol, 40, 509-17.
56. Sankaranarayanan R, Mathew B (1996). Retinoids as cancerpreventive agents. IARC Sci Publ, 139, 47-59.
57. Sanz MA, Martin G, Diaz-Mediavilla J (1998). All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med, 338, 393-4.
58. Scribner DR Jr, Benbrook DM (2002). Retinoids enhance cisplatin-based chemoradiation in cervical cancer cells in vitro. Gynecol Oncol, 85, 223-5.
59. Shutoh M, Oue N, Aung PP, et al (2005). DNA methylation of genes linked with retinoid signaling in gastric carcinoma: expression of the retinoid acid receptor beta, cellular retinolbinding protein 1, and tazarotene-induced gene 1 genes is associated with DNA methylation. Cancer, 104, 1609-19.
60. Shyu RY, Jiang SY, Huang SL, et al (1995). Growth regulation by all-trans-retinoic acid and retinoic acid receptor messenger ribonucleic acids expression in gastric cancer cells. Eur J Cancer, 31A, 237-43.
61. Soprano DR, Qin P, Soprano KJ (2004). Retinoic acid receptors and cancers. Annu Rev Nutr, 24, 201-21.
62. Sun SY, Lotan R (2002). Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol, 41, 41-5.
63. Tanaka T, De Luca LM (2009). Therapeutic potential of "rexinoids" in cancer prevention and treatment. Cancer Res, 69, 4945-7.
64. van der Leede BM, Geertzema J, Vroom TM et al (1996). Immunohistochemical analysis of retinoic acid receptoralpha in human breast tumors: retinoic acid receptor-alpha expression correlates with proliferative activity. Am J Pathol, 148, 1905-14.
65. Wang Q, Wieder R (2004). All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells. Oncogene, 23, 426-33.
66. Wang Q, Yang W, Uytingco MS, Christakos S, Wieder R (2000). 1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death. Cancer Res, 60, 2040-8.
67. White SJ, Freedman LS (1978). Allocation of patients to treatment groups in a controlled clinical study. Br J Cancer, 37, 849-57.
68. Wu Q, Chen Z, Liu S (2000). Mechanism of retinoic acid receptor alpha-mediated growth inhibition of gastric cancer cells by all-trans retinoic acid. Zhonghua Zhong Liu Za Zhi, 22, 195-7.
69. Wu Q, Chen ZM, Su WJ (2002). Anticancer effect of retinoic acid via AP-1 activity repression is mediated by retinoic acid receptor alpha and beta in gastric cancer cells. Int J Biochem Cell Biol, 34, 1102-14.
70. Wu Q, Lin XF, Ye XF, et al (2004). Ubiquitinated or sumoylated retinoic acid receptor alpha determines its characteristic and interacting model with retinoid X receptor alpha in gastric and breast cancer cells. J Mol Endocrinol, 32, 595-613.
71. Xu RC, Zhou YH, Hu WL (2006). Inducement effect of 9-cis retinoic acid on cell cycle arrest and apoptosis of gastric carcinoma cell line MGC803 and its mechanism. Ai Zheng, 25, 1483-7.
72. Ye X, Wu Q, Liu S, Lin X, et al (2004). Distinct role and functional mode of TR3 and RARalpha in mediating ATRAinduced signalling pathway in breast and gastric cancer cells. Int J Biochem Cell Biol, 36, 98-113.
73. Yoshida K, Tanabe K, Fujii D, et al (2003). Induction mechanism of apoptosis by troglitazone through peroxisome proliferatoractivated receptor-gamma in gastric carcinoma cells. Anticancer Res, 23, 267-73.
74. Zanardi S, Serrano D, Argusti A, et al (2006). Clinical trials with retinoids for breast cancer chemoprevention. Endocr Relat Cancer, 13, 51-68.